Clinical Trial

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-21
notable Trial sites expanded: 1 -> 4 locations 2026-07-21
Trial Details
NCT Number NCT07459634
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Ireland Limited
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 50 participants
Start Date 2026-08-30
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20